Previous close | 2.4300 |
Open | 2.4400 |
Bid | 2.2800 x 100 |
Ask | 2.4000 x 100 |
Day's range | 2.3300 - 2.5083 |
52-week range | 2.1600 - 4.6500 |
Volume | |
Avg. volume | 78,538 |
Market cap | 292.729M |
Beta (5Y monthly) | 1.00 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.5100 |
Earnings date | 30 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 4.25 |
SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of th
Looking at Nautilus Biotechnology, Inc.'s ( NASDAQ:NAUT ) insider transactions over the last year, we can see that...
SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023. “2023 was a year of significant accomplishment and foundational progress for Nautilus; progress that will continue to build our momentum as we move through 2024 and into the planned launch of our proteome analysis platform”, said Suj